BACKGROUND: During B-cell development, precursor B cells transiently express the pre-B-cell receptor composed of μ heavy chain complexed with VpreB and λ5 surrogate light chain polypeptides. Recent profiling studies unexpectedly revealed abundant transcripts of one member of the VpreB family, VpreB3, in a subset of mature B cells and Burkitt lymphoma. DESIGN AND METHODS: Here we used a novel antibody to investigate the normal expression pattern of VpreB3 protein in human hematopoietic and lymphoid tissues, and to determine whether VpreB3 could serve as a useful diagnostic biomarker for select B-cell lymphomas. RESULTS: We found that VpreB3 protein is normally expressed by precursor B cells in bone marrow and by a subset of normal germinal center B cells in secondary lymphoid organs. Among lymphoid malignancies, we found an association between VpreB3 expression and B-cell tumors with c-MYC abnormalities. VpreB3 was highly expressed in all cases of Burkitt lymphoma, whether of endemic or sporadic origin (44/44 cases, 100%), all cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (5/5 cases, 100%), and the majority of diffuse large B-cell lymphomas harboring a c-MYC translocation (15/18 cases, 83%). The expression of VpreB3 in diffuse large B-cell lymphomas without a c-MYC translocation was associated with c-MYC polysomy in 25/75 cases (33%) but only rarely observed in diffuse large B-cell lymphomas lacking a c-MYC abnormality (9/98 cases, 9%). CONCLUSIONS: We conclude that for B-cell tumors with features suggesting a possible c-MYC translocation, such as intermediate to large cell size and high proliferation rate, the presence of VpreB3 should prompt subsequent confirmatory genetic testing, whereas the absence of VpreB3 is virtually always associated with wild-type c-MYC alleles.
BACKGROUND: During B-cell development, precursor B cells transiently express the pre-B-cell receptor composed of μ heavy chain complexed with VpreB and λ5 surrogate light chain polypeptides. Recent profiling studies unexpectedly revealed abundant transcripts of one member of the VpreB family, VpreB3, in a subset of mature B cells and Burkitt lymphoma. DESIGN AND METHODS: Here we used a novel antibody to investigate the normal expression pattern of VpreB3 protein in human hematopoietic and lymphoid tissues, and to determine whether VpreB3 could serve as a useful diagnostic biomarker for select B-cell lymphomas. RESULTS: We found that VpreB3 protein is normally expressed by precursor B cells in bone marrow and by a subset of normal germinal center B cells in secondary lymphoid organs. Among lymphoid malignancies, we found an association between VpreB3 expression and B-cell tumors with c-MYC abnormalities. VpreB3 was highly expressed in all cases of Burkitt lymphoma, whether of endemic or sporadic origin (44/44 cases, 100%), all cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (5/5 cases, 100%), and the majority of diffuse large B-cell lymphomas harboring a c-MYC translocation (15/18 cases, 83%). The expression of VpreB3 in diffuse large B-cell lymphomas without a c-MYC translocation was associated with c-MYC polysomy in 25/75 cases (33%) but only rarely observed in diffuse large B-cell lymphomas lacking a c-MYC abnormality (9/98 cases, 9%). CONCLUSIONS: We conclude that for B-cell tumors with features suggesting a possible c-MYC translocation, such as intermediate to large cell size and high proliferation rate, the presence of VpreB3 should prompt subsequent confirmatory genetic testing, whereas the absence of VpreB3 is virtually always associated with wild-type c-MYC alleles.
Authors: Sandeep S Dave; Kai Fu; George W Wright; Lloyd T Lam; Philip Kluin; Evert-Jan Boerma; Timothy C Greiner; Dennis D Weisenburger; Andreas Rosenwald; German Ott; Hans-Konrad Müller-Hermelink; Randy D Gascoyne; Jan Delabie; Lisa M Rimsza; Rita M Braziel; Thomas M Grogan; Elias Campo; Elaine S Jaffe; Bhavana J Dave; Warren Sanger; Martin Bast; Julie M Vose; James O Armitage; Joseph M Connors; Erlend B Smeland; Stein Kvaloy; Harald Holte; Richard I Fisher; Thomas P Miller; Emilio Montserrat; Wyndham H Wilson; Manisha Bahl; Hong Zhao; Liming Yang; John Powell; Richard Simon; Wing C Chan; Louis M Staudt Journal: N Engl J Med Date: 2006-06-08 Impact factor: 91.245
Authors: Jennifer C Paterson; Erica Ballabio; Göran Mattsson; Susan H Turner; David Y Mason; Teresa Marafioti Journal: Appl Immunohistochem Mol Morphol Date: 2008-07
Authors: S Tedoldi; J C Paterson; J Cordell; S-Y Tan; M Jones; S Manek; A P Dei Tos; H Roberton; N Masir; Y Natkunam; S A Pileri; F Facchetti; M-L Hansmann; D Y Mason; T Marafioti Journal: J Pathol Date: 2006-08 Impact factor: 7.996
Authors: H Mossafa; D Damotte; A Jenabian; R Delarue; A Vincenneau; I Amouroux; R Jeandel; E Khoury; J M Martelli; T Samson; S Tapia; G Flandrin; X Troussard Journal: Leuk Lymphoma Date: 2006-09
Authors: Yasodha Natkunam; Shuchun Zhao; David Y Mason; Jun Chen; Behnaz Taidi; Margaret Jones; Anne S Hammer; Stephen Hamilton Dutoit; Izidore S Lossos; Ronald Levy Journal: Blood Date: 2006-10-12 Impact factor: 22.113
Authors: Michael Hummel; Stefan Bentink; Hilmar Berger; Wolfram Klapper; Swen Wessendorf; Thomas F E Barth; Heinz-Wolfram Bernd; Sergio B Cogliatti; Judith Dierlamm; Alfred C Feller; Martin-Leo Hansmann; Eugenia Haralambieva; Lana Harder; Dirk Hasenclever; Michael Kühn; Dido Lenze; Peter Lichter; Jose Ignacio Martin-Subero; Peter Möller; Hans-Konrad Müller-Hermelink; German Ott; Reza M Parwaresch; Christiane Pott; Andreas Rosenwald; Maciej Rosolowski; Carsten Schwaenen; Benjamin Stürzenhofecker; Monika Szczepanowski; Heiko Trautmann; Hans-Heinrich Wacker; Rainer Spang; Markus Loeffler; Lorenz Trümper; Harald Stein; Reiner Siebert Journal: N Engl J Med Date: 2006-06-08 Impact factor: 91.245
Authors: Nam Gyu Im; Amy Guillaumet-Adkins; Jens G Lohr; Birgit Knoechel; Megha Wal; Anna J Rogers; Julia Frede; Claire C Havig; Jing Yang; Praveen Anand; Sarah K Stegmann; Johannes M Waldschmidt; Noori Sotudeh; Leili Niu; Jordan Voisine; Michal R Schweiger; Clemens Grassberger Journal: Cancer Immunol Res Date: 2022-09-01 Impact factor: 12.020
Authors: Miranda H Meeuwsen; Anne K Wouters; Lorenz Jahn; Renate S Hagedoorn; Michel G D Kester; Dennis F G Remst; Laura T Morton; Dirk M van der Steen; Christiaan Kweekel; Arnoud H de Ru; Marieke Griffioen; Peter A van Veelen; J H Frederik Falkenburg; Mirjam H M Heemskerk Journal: Mol Ther Date: 2021-08-08 Impact factor: 11.454
Authors: Ruiyang Liu; Qingsong Gao; Steven M Foltz; Jared S Fowles; Lijun Yao; Julia Tianjiao Wang; Song Cao; Hua Sun; Michael C Wendl; Sunantha Sethuraman; Amila Weerasinghe; Michael P Rettig; Erik P Storrs; Christopher J Yoon; Matthew A Wyczalkowski; Joshua F McMichael; Daniel R Kohnen; Justin King; Scott R Goldsmith; Julie O'Neal; Robert S Fulton; Catrina C Fronick; Timothy J Ley; Reyka G Jayasinghe; Mark A Fiala; Stephen T Oh; John F DiPersio; Ravi Vij; Li Ding Journal: Nat Commun Date: 2021-05-07 Impact factor: 14.919